NRG Oncology Trial Finds No Difference in NeurocoNRG Oncology trial finds no difference in neurocognitive outcomes, but improved overall survival with stereotactic radiosurgery for SCLC brain metastases
Circulating tumor DNA may guide immunotherapy use in limited-stage SCLC, new study shows - EurekAlert!
Tarlatamab with anti-PD-L1 as first-line maintenance after chemo-immunotherapy for ES-SCLC demonstrates acceptable safety profile and unprecedented overall survival - EurekAlert!
Precision medicine in SCLC: DLL3, ASC1, TTF-1, and Ki-67 expression - EurekAlert
